Exome Asset Management LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Exome Asset Management LLC reported 52 stock positions worth $162.1 million. Its top holding was Guardant Health (GH) at 6.2% of the portfolio, followed by Praxis Precision Medicines I (PRAX, 5.6%) and TG Therapeutics (TGTX, 5.6%). Compared with Q1 2026, it opened 15 new positions, sold out of 8, added to 1 and reduced 32. The biggest buy was a new position in TG Therapeutics (TGTX) and the biggest sale Praxis Precision Medicines I (PRAX, shares −40%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002011932
- Portfolio Value
- $162.1M (Q2 2026)
- SEC Filing
- 0001420506-26-001714 ↗ filed Aug 14, 2026
Holdings Value
Holdings 52 stocks · $162.1M
| GH Guardant Health Inc. | 6.25% | 67,500 | $10.1M | Reduce -18.4% |
| PRAX Praxis Precision Medicines I | 5.62% | 27,205 | $9.1M | Reduce -40.2% |
| TGTX TG Therapeutics Inc. | 5.59% | 164,915 | $9.1M | New |
| COGT Cogent Biosciences Inc. | 5.03% | 210,523 | $8.1M | Reduce -24.4% |
| IONS Ionis Pharmaceuticals Inc. | 4.31% | 88,177 | $7.0M | Reduce -19.9% |
| LLY Eli Lilly & Co. | 4.06% | 5,492 | $6.6M | Reduce -21.7% |
| ABVX Abivax SA-ADR | 3.85% | 46,878 | $6.2M | New |
| ALMS Alumis Inc. | 3.55% | 204,418 | $5.8M | Reduce -26.8% |
| CYTK Cytokinetics Inc. | 3.16% | 60,056 | $5.1M | Reduce -42.1% |
| ELVN Enliven Therapeutics Inc. | 3.14% | 100,203 | $5.1M | Reduce -54.5% |
| VERA Vera Therapeutics Inc. | 2.58% | 97,276 | $4.2M | Reduce -15.4% |
| UNH Unitedhealth Group Inc. | 2.46% | 9,612 | $4.0M | Reduce -25.3% |
| TXG 10X Genomics Inc. Class A | 2.43% | 102,629 | $3.9M | Reduce -33.4% |
| NTRA Natera Inc. | 2.31% | 13,800 | $3.7M | Reduce -26.0% |
| QURE Uniqure NV | 2.30% | 81,056 | $3.7M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 2.21% | 32,209 | $3.6M | Reduce -20.6% |
| MAZE Maze Therapeutics Inc. | 2.11% | 114,692 | $3.4M | Add +29.6% |
| GLUE Monte Rosa Therapeutics Inc. | 2.05% | 137,115 | $3.3M | Reduce -23.6% |
| MLTX Moonlake Immunotherapeutics | 2.00% | 166,493 | $3.2M | Reduce -22.7% |
| ALKS Alkermes PLC | 1.98% | 61,336 | $3.2M | Reduce -27.1% |
| LQDA Liquidia Corp. | 1.93% | 39,224 | $3.1M | Reduce -14.3% |
| UTHR United Therapeutics Corp. | 1.81% | 5,410 | $2.9M | Reduce -23.3% |
| GKOS Glaukos Corp. | 1.71% | 19,862 | $2.8M | Reduce -4.8% |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.62% | 32,214 | $2.6M | Reduce -29.5% |
| AGIO Agios Pharmaceuticals Inc. | 1.61% | 70,500 | $2.6M | Reduce -43.6% |
| CBIO Crescent Biopharma Inc. | 1.42% | 127,769 | $2.3M | Reduce -16.6% |
| AZN Astrazeneca PLC | 1.39% | 12,045 | $2.3M | New |
| BSX Boston Scientific Corp. | 1.27% | 48,347 | $2.1M | No change |
| ADAG Adagene Inc.-ADR | 1.27% | 488,293 | $2.1M | Reduce -33.7% |
| PEN Penumbra Inc. | 1.23% | 6,300 | $2.0M | No change |
| ISRG Intuitive Surgical Inc. | 1.20% | 4,908 | $2.0M | Reduce -22.8% |
| VKTX Viking Therapeutics Inc. | 1.15% | 47,861 | $1.9M | New |
| OCUL Ocular Therapeutix Inc. | 1.10% | 181,588 | $1.8M | New |
| EQ Equillium Inc. | 1.09% | 552,956 | $1.8M | New |
| ASND Ascendis Pharma A/S | 1.08% | 6,573 | $1.8M | New |
| CRBP Corbus Pharmaceuticals Holdi | 1.07% | 184,914 | $1.7M | Reduce -21.0% |
| CTMX Cytomx Therapeutics Inc. | 1.06% | 460,067 | $1.7M | Reduce -11.8% |
| VSTM Verastem Inc. | 1.01% | 429,041 | $1.6M | Reduce -32.6% |
| NKTR Nektar Therapeutics | 0.97% | 22,417 | $1.6M | New |
| CLPT Clearpoint Neuro Inc. | 0.92% | 83,636 | $1.5M | New |
| INSM Insmed Inc. | 0.91% | 13,873 | $1.5M | Reduce -48.0% |
| CAI Caris Life Sciences Inc. | 0.86% | 78,180 | $1.4M | New |
| BBIO Bridgebio Pharma Inc. | 0.84% | 18,359 | $1.4M | Reduce -72.8% |
| ZBIO Zenas Biopharma Inc. | 0.82% | 52,443 | $1.3M | Reduce -35.0% |
| NBP Novabridge Biosciences | 0.69% | 576,960 | $1.1M | No change |
| ESTA Establishment Labs Holdings | 0.69% | 13,100 | $1.1M | No change |
| RLAY Relay Therapeutics Inc. | 0.55% | 47,531 | $889K | Reduce -82.9% |
| GERN Geron Corp. | 0.49% | 624,046 | $799K | New |
| DRUG Bright Minds Biosciences Inc. | 0.44% | 10,110 | $710K | New |
| CMPX Compass Therapeutics Inc. | 0.37% | 276,165 | $605K | New |
| REPL Replimune Group Inc. | 0.28% | 40,361 | $447K | New |
| ABUS Arbutus Biopharma Corp. | 0.15% | 50,166 | $241K | Reduce -33.5% |
Portfolio Sells Q1 2026 → Q2 2026
| PRAX Praxis Precision Medicines I | Reduce -40.2% | 5.62% | −3.00 |
| ELV Elevance Health Inc. | Sold out | 0.00% | −2.53 |
| BBIO Bridgebio Pharma Inc. | Reduce -72.8% | 0.84% | −2.11 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −2.02 |
| ELVN Enliven Therapeutics Inc. | Reduce -54.5% | 3.14% | −1.94 |
| INSM Insmed Inc. | Reduce -48.0% | 0.91% | −1.65 |
| AVTX Avalo Therapeutics Inc. | Sold out | 0.00% | −1.40 |
| COGT Cogent Biosciences Inc. | Reduce -24.4% | 5.03% | −1.28 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −1.22 |
| RLAY Relay Therapeutics Inc. | Reduce -82.9% | 0.55% | −1.08 |
| VSTM Verastem Inc. | Reduce -32.6% | 1.01% | −0.97 |
| AGIO Agios Pharmaceuticals Inc. | Reduce -43.6% | 1.61% | −0.88 |
| CYTK Cytokinetics Inc. | Reduce -42.1% | 3.16% | −0.87 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −0.72 |
| NXTC Nextcure Inc. | Sold out | 0.00% | −0.71 |
| UTHR United Therapeutics Corp. | Reduce -23.3% | 1.81% | −0.65 |
| PALI Palisade Bio Inc. | Sold out | 0.00% | −0.62 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -19.9% | 4.31% | −0.55 |
| ISRG Intuitive Surgical Inc. | Reduce -22.8% | 1.20% | −0.52 |
| ADAG Adagene Inc.-ADR | Reduce -33.7% | 1.27% | −0.43 |
| CTMX Cytomx Therapeutics Inc. | Reduce -11.8% | 1.06% | −0.38 |
| MLTX Moonlake Immunotherapeutics | Reduce -22.7% | 2.00% | −0.36 |
| LPCN Lipocine Inc. | Sold out | 0.00% | −0.29 |
| CBIO Crescent Biopharma Inc. | Reduce -16.6% | 1.42% | −0.24 |
| CRBP Corbus Pharmaceuticals Holdi | Reduce -21.0% | 1.07% | −0.22 |
| VERA Vera Therapeutics Inc. | Reduce -15.4% | 2.58% | −0.15 |
| ZBIO Zenas Biopharma Inc. | Reduce -35.0% | 0.82% | −0.11 |
| ALMS Alumis Inc. | Reduce -26.8% | 3.55% | −0.07 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -29.5% | 1.62% | −0.07 |
| ABUS Arbutus Biopharma Corp. | Reduce -33.5% | 0.15% | −0.05 |
| NTRA Natera Inc. | Reduce -26.0% | 2.31% | +0.12 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -20.6% | 2.21% | +0.13 |
| ALKS Alkermes PLC | Reduce -27.1% | 1.98% | +0.23 |
| LLY Eli Lilly & Co. | Reduce -21.7% | 4.06% | +0.27 |
| GLUE Monte Rosa Therapeutics Inc. | Reduce -23.6% | 2.05% | +0.31 |
| GKOS Glaukos Corp. | Reduce -4.8% | 1.71% | +0.39 |
| UNH Unitedhealth Group Inc. | Reduce -25.3% | 2.46% | +0.42 |
| TXG 10X Genomics Inc. Class A | Reduce -33.4% | 2.43% | +0.50 |
| LQDA Liquidia Corp. | Reduce -14.3% | 1.93% | +0.91 |
| GH Guardant Health Inc. | Reduce -18.4% | 6.25% | +1.75 |
Portfolio Buys Q1 2026 → Q2 2026
| TGTX TG Therapeutics Inc. | New | 5.59% | +5.59 |
| ABVX Abivax SA-ADR | New | 3.85% | +3.85 |
| QURE Uniqure NV | New | 2.30% | +2.30 |
| AZN Astrazeneca PLC | New | 1.39% | +1.39 |
| VKTX Viking Therapeutics Inc. | New | 1.15% | +1.15 |
| OCUL Ocular Therapeutix Inc. | New | 1.10% | +1.10 |
| EQ Equillium Inc. | New | 1.09% | +1.09 |
| ASND Ascendis Pharma A/S | New | 1.08% | +1.08 |
| NKTR Nektar Therapeutics | New | 0.97% | +0.97 |
| CLPT Clearpoint Neuro Inc. | New | 0.92% | +0.92 |
| CAI Caris Life Sciences Inc. | New | 0.86% | +0.86 |
| MAZE Maze Therapeutics Inc. | Add +29.6% | 2.11% | +0.56 |
| GERN Geron Corp. | New | 0.49% | +0.49 |
| DRUG Bright Minds Biosciences Inc. | New | 0.44% | +0.44 |
| CMPX Compass Therapeutics Inc. | New | 0.37% | +0.37 |
| REPL Replimune Group Inc. | New | 0.28% | +0.28 |
Options Activity Q1 2026 → Q2 2026
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 60,000 | $7.7Mbefore exit |
| CYTOKINETICS INC | put | Sold out | 60,000 | $4.0Mbefore exit |
| BEIGENE LTD | call | Sold out | 10,000 | $3.0Mbefore exit |
| ALUMIS INC | put | Sold out | 105,000 | $2.3Mbefore exit |
| LIQUIDIA CORPORATION | put | Sold out | 40,000 | $1.5Mbefore exit |
| CENTESSA PHARMACEUTICALS PLC | put | Sold out | 34,700 | $1.4Mbefore exit |
| IDEAYA BIOSCIENCES INC | call | Sold out | 40,000 | $1.3Mbefore exit |
| IDEAYA BIOSCIENCES INC | put | Sold out | 40,000 | $1.3Mbefore exit |
| TRAVERE THERAPEUTICS INC | put | Sold out | 20,000 | $594Kbefore exit |
| WAVE LIFE SCIENCES LTD | put | Sold out | 30,000 | $218Kbefore exit |
| COMPASS THERAPEUTICS INC | call | Sold out | 25,100 | $133Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 52 | $162.1M | GH, PRAX, TGTX, COGT, IONS |
| Q1 2026 | 45 | $169.9M | PRAX, COGT, ELVN, IONS, GH |
| Q4 2025 | 53 | $202.4M | PRAX, COGT, GH, IONS, LLY |
| Q3 2025 | 54 | $151.4M | IONS, CYTK, BBIO, COGT, GH |
| Q2 2025Amended | 55 | $121.3M | ISHARES TR, BBIO, GH, GERN, IONS |
| Q1 2025Amended | 49 | $111.6M | BBIO, GH, GERN, AZN, CYTK |
| Q4 2024 | 58 | $132.9M | BBIO, LLY, GERN, HUM, GH |
| Q3 2024Amended | 59 | $147.9M | LLY, ASND, BBIO, GPCR, TGTX |
| Q2 2024Amended | 52 | $112.3M | LLY, SRPT, ONC, TGTX, CI |
| Q1 2024 | 53 | $116.8M | LLY, RDY, ONC, CI, ALPN |